NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW) today announced that a pre-New Drug Application (“NDA”) meeting with the U.S. Food & Drug Administration (“FDA”) is scheduled for December 22nd for DAVANAT® under Section 505 (b)(2) to be co-administered with 5-Fluorouracil (5-FU) to treat late-stage colorectal cancer patients.
